Latest News for: GlaxoSmithKline

Edit

Transmission of Half Yearly Report for the Period ended June 30, 2025 (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 29 Aug 2025
The Directors of GlaxoSmithKline Pakistan Limited (the "Company") are pleased to present the un-audited financial information of your Company for the six months period ended June 30, 2025 ... TO THE MEMBERS OF GLAXOSMITHKLINE PAKISTAN LIMITED.
Edit

Breaking the Silence on Gynaecological Cancers: Empowering Canadian Women to Take Action (GSK - GlaxoSmithKline Inc)

Public Technologies 27 Aug 2025
). - Canadian survey highlights gaps in awareness and urges proactive conversations on symptoms, risk factors and prevention strategies ... A Silent Health Concern to Women's Health ... Barriers to Awareness and Action ... About GSK ... i ... v ... GSK - GlaxoSmithKline Inc.
Edit

Financial Results for the Quarter ended June 30, 2025 (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 26 Aug 2025
GlaxoSmithKline Pakistan Limited 35-Dockyard Road, West Wharf, Karachi - 74000, Pakistan ... This is to inform you that the Board of Directors of GlaxoSmithKline Pakistan Limited in their meeting held on Tuesday, August 26, 2025, at 12.30 p.m.
Edit

Enterprise leaders say recipe for AI agents is matching them to existing processes — not ...

Venture Beat 26 Aug 2025
Global enterprises Block and GlaxoSmithKline (GSK) are exploring AI agent proof of concepts in financial services and drug discovery. Read More ....
Edit

Notice of Board of Directors Meeting (Q2- 2025) (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 19 Aug 2025
). August 19"' 2025. The General Manager. Pa1‹istan Stocl‹ Exchange Liliiited Stock Exchange Building. Stoclt Excli‹inge Road, Karachi 74000. GlaxoSmithKline Pakistan Limited ... T +92 21 111 475 725. Dear Sir,. Subject ... GSK - GlaxoSmithKline Pakistan Ltd.
Edit

Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch ...

GetNews 05 Aug 2025
Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch ... GlaxoSmithKline.
Edit

Half-year Report (GlaxoSmithKline Capital plc)

Public Technologies 30 Jul 2025
) GlaxoSmithKline Capital plc ... WC1A 1DG GlaxoSmithKline Capital plc (Registered number ... GlaxoSmithKline Capital plc (the "Company") is a member of the GSK Group (the "Group").
Edit

Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., ...

GetNews 28 Jul 2025
Key companies developing therapies for Migraine are - GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.
Edit

Pertussis Market Analysis and Forecast Report 2025-2035, Competitive Profiles of GlaxoSmithKline, Mitsubishi Tanabe Pharma, Sanofi, ...

The Galveston Daily News 25 Jul 2025
DUBLIN--(BUSINESS WIRE)--Jul 25, 2025-- ....
Edit

Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma (GSK - GlaxoSmithKline Inc)

Public Technologies 23 Jul 2025
Superior efficacy results, when compared to standard of care, from the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma support the approval of the Blenrep combinations ... About Blenrep ... GSK - GlaxoSmithKline Inc.
Edit

Chronic Rhinosinusitis with Nasal Polyps Market Analysis and Forecast Report 2025-2035, Featuring AstraZeneca, Amgen, GlaxoSmithKline, ...

Nasdaq Globe Newswire 15 Jul 2025
The global chronic rhinosinusitis with nasal polyps market is experiencing growth, driven by the uptake of biologic therapies like dupilumab and mepolizumab that effectively target inflammatory pathways ... .
Edit

Asthma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | GlaxoSmithKline, ...

GetNews 02 Jul 2025
GlaxoSmithKline ... Around 80 leading companies are actively involved in developing asthma therapies, with GlaxoSmithKline being a notable player, as its drug candidates for asthma are currently in the advanced Phase III stage of development.
Edit

CTD-ILD Market Growth Projections 2024-2034: DelveInsight Analysis | GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, ...

GetNews 30 Jun 2025
The Key CTD-ILD Companies in the market include - GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others ... GlaxoSmithKline ... GlaxoSmithKline plc.
Edit

Valadez v. GlaxoSmithKline LLC (Illinois Courts)

Public Technologies 27 Jun 2025
) GLAXOSMITHKLINE LLC, GLAXOSMITHKLINE ) HOLDINGS (AMERICAS) INC., GLAXOSMITHKLINE ) PLC, BOEHRINGER INGELHEIM ) PHARMACEUTICALS, INC., BOEHRINGER ) INGELHEIM INTERNATIONAL GMBH, ).
Edit

Jemperli receives positive funding recommendations from CDA-AMC and INESSS in all adult patients with primary advanced or first recurrent endometrial cancer (GSK - GlaxoSmithKline Inc)

Public Technologies 26 Jun 2025
HTA recommendation marks an important step toward securing public funding for eligible patients in Canada, with provincial and territorial governments ultimately responsible for making the final decision on public coverage ... GSK - GlaxoSmithKline Inc.

Article Search

tools
×
×
×
×